Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen
NN8022-4392
Phase 3 small_molecule active
Quick answer
Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen for Obesity is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Obesity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active